Biocon Biologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon, has announced a collaboration with Civica, Inc.
Under this agreement, Biocon Biologics will supply the Insulin Aspart drug substance to Civica, which will be used to produce the final Insulin Aspart drug product.
Enhancing access
Civica will commercialise the medicine in the US following the completion of development work and clinical trials. The agreement does not involve any technology transfer. According to the company, this collaboration aims to enhance access and affordability of Insulin Aspart in the US.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, stated, “Our collaboration with Civica enables us to expand patient access to Insulin Aspart in the US.”
This partnership is in addition to Biocon Biologics’ own Insulin Aspart drug product, which is currently under review by the US Food and Drug Administration (FDA).
